“`html
U.S. Obesity Rate Declines, But Diabetes Cases Continue to Surge
Table of Contents
Published: October 26, 2023 (Updated: October 26, 2023)
Washington D.C. – In a surprising turn of events, the U.S. adult obesity rate has begun to fall, according to the latest data from Gallup. After reaching a peak of 39.9% in 2022, the rate has declined to 37.0% in 2025. This represents a statistically meaningful decrease, equating to approximately 7.6 million fewer obese adults compared to three years prior.
Diabetes Diagnoses Hit All-Time High
However, the positive trend in obesity rates is shadowed by a concerning rise in diabetes diagnoses. The prevalence of diabetes – a chronic condition requiring lifelong management – has reached a record high of 13.8% nationwide. Both the obesity rate and diabetes statistics are tracked as part of the ongoing Gallup National Health and Well-Being Index.
Growing Popularity of GLP-1 Medications
The decline in obesity rates coincides with increased use of Type 2 antidiabetic GLP-1 drugs, such as semaglutide (marketed as Ozempic and Wegovy), for weight loss. The percentage of adults reporting use of these medications specifically for weight loss has more than doubled in the past year, rising from 5.8% in February 2024 to 12.4% currently.
Usage is more pronounced among women, with 15.2% reporting use compared to 9.7% of men. Public awareness of these weight loss drugs has also increased substantially, jumping from 80% to 89% nationally during the same period.
news.gallup.com/poll/696599/obesity-rate-declining.aspx">“These findings suggest a potential shift in the landscape of weight management in the U.S., though the long-term implications remain to be seen.”
Gallup National Health and Well-Being Index
The rise of GLP-1 drugs represents a new approach to weight management, but experts caution that lifestyle changes – including diet and exercise – remain crucial for sustained health. The long-term effects of these medications are still under inquiry.
Key Statistics
| Metric | 2022 | 2025 | February 2024 (GLP-1 usage) | Current (GLP-1 Usage) |
|---|---|---|---|---|
| Obesity Rate | 39.9% | 37.0% | N/A | N/A |
| Diabetes Diagnoses | N/A | 13.8% | N/A | N/A |
| GLP-1 Usage (Weight Loss) | N/A | N/A | 5.8% | 12.4% |
This is
